Information Library

Business transformation - Cost control/reduction

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • QUINTILES EXAMINES ASIA-PACIFIC DRUG DEVELOPMENT LANDSCAPE IN NEW REPORT

    March 17, 2010 - A new report from Quintiles analyzes the Asia-Pacific pharmaceutical development landscape and its evolution from outsourcing destination to potential innovation hub.

  • QUINTILES AND MOVETIS ANNOUNCE STRATEGIC ALLIANCE

    January 28, 2010 - Quintiles announced a strategic alliance with Movetis NV for commercialization of its new product, Resolor (prucalopride), in the U.K. and Germany.

  • QUINTILES OPENS EXPANDED ASIA-PACIFIC HEADQUARTERS IN SINGAPORE

    November 6, 2009 - To meet the growing demand for its services throughout the Asia-Pacific region, Quintiles announced the official grand opening of its expanded Asia-Pacific regional headquarters facility in Singapore's Science Park I.

  • Anatomy of a Managed Partnership

    May 26, 2009
    Partnering affords pharma the opportunity to bolster development pipelines without taking on additional risk or adding to fixed costs.

  • Jim Featherstone, Ph.D.

    March 25, 2009
    Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice.

  • Matthew Eberhart

    March 25, 2009
    Matt is a proven business-building executive with a strong track record of implementing successful business development initiatives for consulting healthcare companies in both North America and Europe.

  • Gain Capital & Retain Value

    March 24, 2009
    Cell Therapeutics was in need of capital to fund ongoing development expenses, but was not interested in further equity dilution. As an alternative, they considered monetizing a royalty interest in Trisenox®, their only marketed oncology product.

  • Reducing Risk

    August 1, 2008
    A Pharma TV interview with Ben Cons

  • The Next Generation of Partnerships

    August 1, 2008
    A Pharma TV interview with Ben Cons

  • Pressures and Opportunities

    August 1, 2008
    A Pharma TV interview with Ben Cons

Page 1 of 1 (10 results)

Tell Us What You Think

Rate your Quintiles.com experience

Subscribe to Email Based on Your Interests

Set preferences